Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, long-lasting autoimmune disease that can worsen over time. CIDP occurs when the immune system mistakenly attacks the covering of some nerve cells in the arms and legs. CIPD can lead to difficulty walking or performing typical daily tasks without help.

The Emlight study is designed to determine the correct dose of the investigational study drug in adolescent participants.  It also aims to evaluate if the investigational study drug* may work (also known as efficacy) and how safe it is for the use in children living with CIDP.

*The investigational study drug, empasiprubart, is not approved by any regulatory agency for use in CIDP as efficacy and safety have not been established.

Your child may be eligible to participate if they are:

• Between 12 and less than 18 years of age
• Diagnosed with CIDP

Additional criteria to participate apply which the study doctor will discuss with you.

If your child joins, they will participate in the study for up to 43 months (almost 3,5 years) . During this time, they may need to visit the study site up to 38 times. Some visits will be at the study site, and others could be at your home or another location.
The study consists of 3 phases:

• Screening phase: up to 8 weeks (approximately 2 months).
• Open label treatment phase: will be up to 120 weeks (approximately 27 months). The investigational study drug will be given through an infusion into a vein in your child’s arm (intravenously).
• Safety follow up phase: will be up to 60 weeks (approximately 14 months) after the last dose